Interstitial pneumonitis associated with trastuzumab emtansine.
Ali AlkanPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2018)
Trastuzumab emtansine is an antibody-drug conjugate that is effective in human epidermal growth factor receptor-2 expressing advanced breast cancer. Trastuzumab emtansine is generally well tolerated and grade 3-4 toxicities are rare. Pulmonary complications were rarely reported. Here we present a patient presenting with dyspnea after trastuzumab emtansine therapy and treated with a diagnosis of interstitial pneumonitis.
Keyphrases
- epidermal growth factor receptor
- metastatic breast cancer
- positive breast cancer
- tyrosine kinase
- advanced non small cell lung cancer
- case report
- endothelial cells
- pulmonary hypertension
- interstitial lung disease
- risk factors
- stem cells
- cancer therapy
- mesenchymal stem cells
- induced pluripotent stem cells
- palliative care
- newly diagnosed
- cell therapy